International Assets Investment Management LLC Purchases 30,124 Shares of Johnson & Johnson (NYSE:JNJ)

International Assets Investment Management LLC lifted its position in Johnson & Johnson (NYSE:JNJGet Rating) by 185.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,357 shares of the company’s stock after acquiring an additional 30,124 shares during the quarter. International Assets Investment Management LLC’s holdings in Johnson & Johnson were worth $2,761,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Sterling Investment Advisors Ltd. grew its stake in shares of Johnson & Johnson by 2.8% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 58,608 shares of the company’s stock worth $10,387,000 after acquiring an additional 1,620 shares in the last quarter. Bray Capital Advisors grew its position in Johnson & Johnson by 0.4% during the first quarter. Bray Capital Advisors now owns 28,296 shares of the company’s stock valued at $5,015,000 after buying an additional 126 shares during the period. Leo Brokerage LLC bought a new position in Johnson & Johnson during the first quarter valued at about $53,303,000. Fusion Capital LLC grew its position in Johnson & Johnson by 7.8% during the first quarter. Fusion Capital LLC now owns 27,844 shares of the company’s stock valued at $4,935,000 after buying an additional 2,019 shares during the period. Finally, State of New Jersey Common Pension Fund D grew its position in Johnson & Johnson by 0.3% during the first quarter. State of New Jersey Common Pension Fund D now owns 1,545,930 shares of the company’s stock valued at $273,985,000 after buying an additional 3,989 shares during the period. Institutional investors own 68.78% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. The Goldman Sachs Group increased their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Morgan Stanley increased their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report on Friday, July 8th. Raymond James upped their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Finally, Citigroup dropped their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Trading Down 0.3 %

Shares of Johnson & Johnson stock opened at $173.91 on Tuesday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a market cap of $457.63 billion, a price-to-earnings ratio of 25.31, a PEG ratio of 3.32 and a beta of 0.59. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The company’s 50-day moving average price is $175.84 and its 200-day moving average price is $174.50.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same period in the prior year, the firm posted $2.48 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.60%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s payout ratio is 65.79%.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.